Table 3.
Antigen | Controls n (%) | Cases n (%) | OR (95%CI)a | p-valuea | pinteraction | ||
---|---|---|---|---|---|---|---|
Overall | Gallo2178 | Neg | 519 (90) | 493 (86) | |||
Pos | 57 (10) | 83 (14) | 1.57 (1.09–2.27) | 0.016 | |||
FliC Q1/Q2 | Gallo2178 | Neg | 256 (89) | 238 (91) | |||
Pos | 32 (11) | 24 (9) | 0.85 (0.48–1.49) | 0.564 | |||
FliC Q3/Q4 | Gallo2178 | Neg | 263 (91) | 255 (81) | |||
Pos | 25 (9) | 59 (19) | 2.42 (1.45–4.06) | 0.0007 | 0.007 | ||
Overall | Gallo2179 | Neg | 520 (90) | 495 (86) | |||
Pos | 56 (10) | 81 (14) | 1.46 (1.01–2.11) | 0.045 | |||
FliC Q1/Q2 | Gallo2179 | Neg | 262 (91) | 232 (89) | |||
Pos | 26 (9) | 30 (11) | 1.26 (0.72–2.20) | 0.427 | |||
FliC Q3/Q4 | Gallo2179 | Neg | 258 (90) | 263 (84) | |||
Pos | 30 (10) | 51 (16) | 1.63 (0.99–2.68) | 0.056 | 0.499 |
aLogistic regression model with adjustment for age, sex, province, education, BMI, smoking and family history of CRC; significant associations (p-value < 0.05) are marked in bold font.